WO2007031273A3 - Artificial immune-reconstituted epidermis equivalents - Google Patents

Artificial immune-reconstituted epidermis equivalents Download PDF

Info

Publication number
WO2007031273A3
WO2007031273A3 PCT/EP2006/008872 EP2006008872W WO2007031273A3 WO 2007031273 A3 WO2007031273 A3 WO 2007031273A3 EP 2006008872 W EP2006008872 W EP 2006008872W WO 2007031273 A3 WO2007031273 A3 WO 2007031273A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune
epidermis
skin
reconstituted epidermis
reconstituted
Prior art date
Application number
PCT/EP2006/008872
Other languages
French (fr)
Other versions
WO2007031273A2 (en
Inventor
Bernhard Moser
Patrick Schaerli
Original Assignee
Univ Bern
Bernhard Moser
Patrick Schaerli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bern, Bernhard Moser, Patrick Schaerli filed Critical Univ Bern
Publication of WO2007031273A2 publication Critical patent/WO2007031273A2/en
Publication of WO2007031273A3 publication Critical patent/WO2007031273A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues
    • C12N2503/06—Screening or testing on artificial skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Abstract

The invention relates to a method of preparation of a novel human immune-reconstituted epidermis equivalent comprising culturing epidermis precursor cells from skin biopsies or outer root sheaths of hair follicles and then co-culturing this epidermis equivalent with human peripheral blood mononuclear cells expressing CD14 on a solid support, and to such novel human immune-reconstituted epidermis equivalent prepared by this method and comprising progeny of human peripheral blood mononuclear cells originally expressing CD14. The invention further relates to the use of these immune-reconstituted epidermis equivalents in assays relating to immune reactivity and skin-damaging properties of immunogenic and potentially harmful substances as well as to the use of these immune-reconstituted epidermis equivalents in immunotherapy of skin lesions, inflammation and skin diseases caused by pathogens or tumors.
PCT/EP2006/008872 2005-09-16 2006-09-12 Artificial immune-reconstituted epidermis equivalents WO2007031273A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05405543.9 2005-09-16
EP05405543 2005-09-16

Publications (2)

Publication Number Publication Date
WO2007031273A2 WO2007031273A2 (en) 2007-03-22
WO2007031273A3 true WO2007031273A3 (en) 2007-05-03

Family

ID=37709597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008872 WO2007031273A2 (en) 2005-09-16 2006-09-12 Artificial immune-reconstituted epidermis equivalents

Country Status (1)

Country Link
WO (1) WO2007031273A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB2485816A (en) * 2010-11-25 2012-05-30 Alcyomics Ltd In vitro model for the prediction of immunogenicity, hypersensitivity or allergenicity
FR3132146A1 (en) * 2022-01-27 2023-07-28 Genoskin Ex vivo human model intended for the evaluation of the vaccine potential of a composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228686A1 (en) * 2002-06-07 2003-12-11 Mattek Corporation Three dimensional vaginal tissue model containing immune cells
EP0789074B1 (en) * 1996-01-23 2003-12-17 L'oreal Skin equivalent containing Langerhans cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789074B1 (en) * 1996-01-23 2003-12-17 L'oreal Skin equivalent containing Langerhans cells
US20030228686A1 (en) * 2002-06-07 2003-12-11 Mattek Corporation Three dimensional vaginal tissue model containing immune cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FACY V ET AL: "Reactivity of Langerhans cells in human reconstructed epidermis to known allergens and UV radiation.", TOXICOLOGY IN VITRO, vol. 19, no. 6, September 2005 (2005-09-01), pages 787 - 795, XP004944806, ISSN: 0887-2333 *
LIMAT A & HUNZIKER T: "Use of epidermal equivalents generated from follicular outer root sheath cells in vitro and for autologous grafting of chronic wounds.", CELLS, TISSUES, ORGANS, vol. 172, no. 2, 2002, pages 79 - 85, XP008074938, ISSN: 1422-6405 *
PONEC M: "Skin constructs for replacement of skin tissues for in vitro testing.", ADVANCED DRUG DELIVERY REVIEWS, vol. 54 Suppl 1, 1 November 2002 (2002-11-01), pages S19 - S30, XP002419725, ISSN: 0169-409X *
SIVARD P ET AL: "In vitro reconstructed mucosa-integrating Langerhans' cells.", EXPERIMENTAL DERMATOLOGY AUG 2003, vol. 12, no. 4, August 2003 (2003-08-01), pages 346 - 355, XP002295352, ISSN: 0906-6705 *

Also Published As

Publication number Publication date
WO2007031273A2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
EP2361930A3 (en) Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2019316A3 (en) Ex vivo human skin model
WO2006065495A3 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
WO2009044379A3 (en) Optimised and defined method for isolation and preservation of precursor cells from human umbilical cord
WO2012174239A3 (en) Autologous in situ tissue engineering
BR112013004914A2 (en) "skin compositions and methods of their use".
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
WO2008008770A3 (en) 6, 9-disubstituted purine derivatives and their use for treating skin
WO2011009712A3 (en) Hair conditioners comprising selected cationic silicones and dimethicone
WO2011031077A3 (en) Production method for cryopreserved acellular dermal matrix, and cryopreserved acellular dermal matrix produced thereby
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
IL189281A0 (en) In vitro diagnostic method and kit for identification of human papillomavirus in clinical samples
ZA200608996B (en) Use of XIKVAV peptides in the preparation of cosmetic compositions which are intended to improve the firmness of the skin by increasing cell adhesion
IL205968A0 (en) Mixed butyric formic esters of acid polysaccharides, and their preparation and use as skin cosmetics
EP2324766A3 (en) Micro-insult test and use therefor
WO2007031273A3 (en) Artificial immune-reconstituted epidermis equivalents
Cervelli et al. Treatment of stable vitiligo by ReCell system
WO2004044155A8 (en) MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
EP1708757A4 (en) Use of human cord blood-derived pluripotent cells for the treatment of disease
BRPI0600326A (en) physiologically acceptable composition, cosmetic uses, cosmetic treatment uses and processes
BRPI0716107A2 (en) Methods for making langerhan cells or dendritic cells and for differentiating monocytes, cell model, frozen cd14 + monocytes, use of at least one cell model and / or at least one tissue model, and methods for producing a tissue model , and a reconstructed skin or a reconstructed mucosa
WO2013093069A3 (en) Moisturizing composition
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
BRPI0908316A2 (en) "In vitro or in vivo method of compound selection, use and cosmetic use of a human cidea protein modulator, in vitro diagnostic or monitoring methods and determination of an individual's susceptibility to acne development and gene or protein uses cidea "

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06805698

Country of ref document: EP

Kind code of ref document: A2